Shattuck Labs (NASDAQ:STTK) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Shattuck Labs (NASDAQ:STTK) issued its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01, FiscalAI reports. The firm had revenue of $1.00 million during the quarter.

Shattuck Labs Stock Up 1.0%

Shares of Shattuck Labs stock traded up $0.02 on Friday, hitting $1.98. 101,064 shares of the company were exchanged, compared to its average volume of 224,799. The company has a 50-day moving average price of $1.99 and a 200 day moving average price of $1.30. The stock has a market capitalization of $94.84 million, a price-to-earnings ratio of -1.94 and a beta of 1.88. Shattuck Labs has a 1-year low of $0.69 and a 1-year high of $2.71.

Wall Street Analyst Weigh In

A number of research firms have recently commented on STTK. Needham & Company LLC restated a “hold” rating on shares of Shattuck Labs in a research report on Thursday, August 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Shattuck Labs in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Shattuck Labs from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Wedbush started coverage on shares of Shattuck Labs in a research report on Monday, September 8th. They set an “outperform” rating and a $4.00 price target for the company. Finally, Leerink Partners decreased their price target on shares of Shattuck Labs from $4.00 to $2.00 and set an “outperform” rating on the stock in a research note on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $3.00.

Insider Buying and Selling

In related news, Director Orbimed Advisors Llc bought 6,306,127 shares of the business’s stock in a transaction on Monday, August 25th. The stock was acquired at an average cost of $0.87 per share, with a total value of $5,486,330.49. Following the purchase, the director directly owned 5,255,106 shares of the company’s stock, valued at $4,571,942.22. The trade was a -600.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Mona Ashiya purchased 6,306,127 shares of Shattuck Labs stock in a transaction dated Monday, August 25th. The shares were bought at an average price of $0.87 per share, for a total transaction of $5,486,330.49. Following the acquisition, the director owned 5,255,106 shares in the company, valued at approximately $4,571,942.22. This trade represents a -600.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 12.00% of the company’s stock.

Institutional Investors Weigh In On Shattuck Labs

Several hedge funds and other institutional investors have recently bought and sold shares of STTK. Bridgeway Capital Management LLC boosted its holdings in Shattuck Labs by 147.5% in the 2nd quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock valued at $73,000 after purchasing an additional 55,000 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Shattuck Labs during the 1st quarter valued at approximately $81,000. Acadian Asset Management LLC raised its position in shares of Shattuck Labs by 27.6% during the 1st quarter. Acadian Asset Management LLC now owns 257,345 shares of the company’s stock valued at $243,000 after buying an additional 55,687 shares during the period. Jane Street Group LLC lifted its holdings in Shattuck Labs by 2,510.8% in the second quarter. Jane Street Group LLC now owns 289,671 shares of the company’s stock valued at $229,000 after acquiring an additional 278,576 shares during the last quarter. Finally, Qube Research & Technologies Ltd purchased a new position in Shattuck Labs in the second quarter worth approximately $44,000. 58.74% of the stock is currently owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.